Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:immunotherapy
|
| gptkbp:administered_by |
oral capsule
intravenous injection ointment |
| gptkbp:approves |
gptkb:1997
gptkb:FDA |
| gptkbp:available_on |
generic drug
branded drug |
| gptkbp:brand |
Astagraf XL
Envarsus XR Prograf |
| gptkbp:casnumber |
104987-11-3
|
| gptkbp:chemical_formula |
C44 H69 N1 O12
|
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:contraindication |
active infections
hypersensitivity to tacrolimus severe liver dysfunction |
| gptkbp:developed_by |
Streptomyces tsukubaensis
|
| gptkbp:discovered_by |
gptkb:1980s
|
| gptkbp:duration |
varies by condition
long-term for transplant patients short-term for dermatitis |
| gptkbp:formulation |
oral
topical injectable |
| https://www.w3.org/2000/01/rdf-schema#label |
tacrolimus
|
| gptkbp:interacts_with |
with azole antifungals
with calcium channel blockers with grapefruit juice with macrolide antibiotics with NSAIDs |
| gptkbp:is_monitored_by |
electrolytes
blood pressure kidney function liver function tests |
| gptkbp:lifespan |
approximately 12 hours
|
| gptkbp:mechanism_of_action |
inhibits T-lymphocyte activation
|
| gptkbp:pharmacokinetics |
highly protein-bound
metabolized by CYP3 A4 |
| gptkbp:side_effect |
nausea
gastrointestinal disturbances high blood pressure kidney damage increased risk of infections tremors neurotoxicity hyperlipidemia hyperglycemia nephrotoxicity |
| gptkbp:used_for |
preventing organ transplant rejection
treating atopic dermatitis |
| gptkbp:bfsParent |
gptkb:Protopic
|
| gptkbp:bfsLayer |
7
|